ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiskott-Aldrich syndrome  (1)
  • high-throughput screening  (1)
  • 1
    ISSN: 1573-4986
    Keywords: glycosyltransferase ; assay ; high-throughput screening ; drug discovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Notes: Abstract Glycosyltransferases mediate changes in glycosylation patterns which, in turn, may affect the function of glycoproteins and/or glycolipids and, further downstream, processes of development, differentiation, transformation and cell-cell recognition. Such enzymes, therefore, represent valid targets for drug discovery. We have developed a solid-phase glycosyltransferase assay for use in a robotic high-throughput format. Carbohydrate acceptors coupled covalently to polyacrylamide are coated onto 96-well plastic plates. The glycosyltransferase reaction is performed with recombinant enzymes and radiolabeled sugar-nucleotide donor at 37°C, followed by washing, addition of scintillation counting fluid, and measurement of radioactivity using a 96-well β-counter. Glycopolymer construction and coating of the plastic plates, enzyme and substrate concentrations, and linearity with time were optimized using recombinant Core 2 β1-6-N-acetylglucosaminyltransferase (Core 2 GlcNAc-T). This enzyme catalyzes a rate-limiting reaction for expression of polylactosamine and the selectin ligand sialyl-Lewisx in Ο-glycans. A glycopolymer acceptor for β1-6-N-acetylglucosaminyltransferase V was also designed and shown to be effective in the solid-phase assay. In a high-throughput screen of a microbial extract library, the coefficient of variance for positive controls was 9.4%, and high concordance for hit validation was observed between the Core 2 GlcNAc-T solid-phase assay and a standard solution-phase assay. The solid-phase assay format, which can be adapted for a variety of glycosyltransferase enzymes, allowed a 5–6 fold increase in throughput compared to the corresponding solution-phase assay.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1573-4986
    Keywords: immunodeficiency ; N-acetylglucosaminyltransferase ; O-glycosylation ; Wiskott-Aldrich syndrome
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Notes: Abstract Serine/threonine (O)-linked oligosaccharide on cell-surface CD43 has been reported to be abnormal in haemopoietic lineages of patients with the X-linked immunodeficiency, Wiskott-Aldrich syndrome (WAS). This defect largely appears to be the result of abnormal regulation of UDP-GlcNAc:Galβ1-3GalNAc-Rβ1-6-N-acetylglucosaminyltransferase (also known as core 2 GlcNAc-T), an enzyme in the Golgi apparatus that is subject to regulation during haemopoietic differentiation. To determine whether core 2 GlcNAc-T activity provides a reliable marker for WAS, we studied 12 unrelated WAS patients with respect to their expression of this enzyme activity. Compared with healthy subjects, the WAS patients showed levels of core 2 activity that were, on average, 2.5- and 3.9-fold higher in fresh lymphocytes and platelets respectively. These data suggest that altered core 2 GlcNAc-T activity is consistently found in lymphocytes and platelets of WAS patients and as such may provide a diagnostic marker for the disease. In view of the relatively limited amounts of blood sample generally available from infants and young children, we have also tested a more sensitive coupled assay that permits assessment of core 2 GlcNAc-T activity in very small samples of cells and which would therefore render this assay of wide clinical applicability.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...